Psoriasis drug may affect birth control: small study investigates

NCT ID NCT07181343

Completed Knowledge-focused Sponsor: Hansoh BioMedical R&D Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 trial in 18 healthy women aged 18–40 tested whether taking the experimental psoriasis drug HS-10374 changes how the body absorbs and clears the birth control pill Yasmin. Participants took Yasmin alone and then again after a course of HS-10374. Researchers measured drug levels in the blood to see if there is a meaningful interaction. The results will guide safe co-prescribing for women with psoriasis who need contraception.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-10374 tablets and drospirenone/ethinyl estradiol (Yasmin) tablets
What this could lead to: If successful, this study will show whether HS-10374 changes how the body processes Yasmin, helping doctors prescribe both safely together for women with psoriasis.
What could go wrong: This is a small, early-phase study in healthy volunteers, not patients. It only measures drug levels, not real-world effectiveness or side effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS (PSO) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS (PSO)

Contacts and locations

Locations

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.